$13.80
+0.072%Enhabit, Inc. provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services. The company also offers hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement counseling services to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. As of March 31, 2022, it operated in 252 home health agencies and 99 hospice agencies across 34 states. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was incorporated in 2014 and is headquartered in Dallas, Texas. As of July 1, 2022, Enhabit, Inc. operates as a standalone company.
Negative free cash flow despite positive earnings raises concerns about cash generation ability or heavy capital requirements.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
EHAB โข NYSE
| Enhabit, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||
-2.6M | -154M | -80.5M | -38.3M | 112.9M | 75M | 24.8M | |
22.5M | 31.5M | 30.9M | 33M | 36.9M | 40M | 37.7M | |
0.0 | -5.7M | -11.6M | -4.3M | 8.6M | 18.5M | 2.1M | |
16.6M | 11.7M | 8.9M | 9.2M | 3.6M | 0.0 | 84.9M | |
30.4M | 162.6M | 89M | 109.7M | -5.9M | 3.5M | -700K | |
(0.0) | (0.0) | (0.0) | (11.9M) | (28.4M) | (0.0) | (22M) | |
3.8M | 5.1M | 11.7M | -29.2M | -32.8M | -112.1M | -89.3M | |
70.7M | 51.2M | 48.4M | 80.1M | 123.3M | 24.9M | 59.5M | |
INVESTING ACTIVITIES | |||||||
-4.9M | -3.8M | -3.5M | -7.1M | -4.3M | -3.6M | -12.1M | |
(0.0) | (0.0) | -2.8M | -36.3M | -117.5M | -1.1M | -231.5M | |
1.8M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
19.8M | 1.4M | 1M | 1.1M | 2.6M | 1.7M | -2.4M | |
(16.7M) | -2.4M | -5.3M | -42.3M | -119.2M | -3M | -246M | |
FINANCING ACTIVITIES | |||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 124M | 0.0 | |
-67.7M | -43.6M | -33.4M | 575M | -7.2M | 5.1M | 189M | |
(0.0) | (0.0) | (0.0) | -654.9M | -154.1M | -144.5M | -4.9M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -4.9M | |
-4.5M | -4.7M | -7.1M | 61.3M | 125.2M | -1.3M | 14.1M | |
-72.2M | -48.3M | -40.5M | -18.6M | -36.1M | -16.7M | 198.2M | |
CASH FLOW SUMMARY | |||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 34.8M | 0.0 | |
15.2M | 500K | 2.6M | 19.2M | -32M | 40M | 11.7M | |
30.3M | 29.8M | 27.2M | 8M | 40M | 0.0 | 23.1M | |
45.5M | 30.3M | 29.8M | 27.2M | 8M | 40M | 34.8M | |
65.8M | 47.4M | 44.9M | 73M | 119M | 21.7M | 47.4M |
EHAB - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 15, 2026 | May 15, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
10-K/A 10-K/A 2025 FY (Amended) FY | April 30, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | April 16, 2026 | April 15, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 05, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 05, 2026 | March 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 04, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 27, 2026 | February 24, 2026 | 2026 |
Continue your EHAB research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.